Euronext announces volumes for December 2025 Euronext announces volumes for December 2025 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 8 January 2026 – Euronext, the leading European capital market infrastructure, today announced trading volumes for December 2025. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Judith Stein 97 Margaux Kurver 03 MEDIA – Europe Andrea Monzani 13 Sandra Machado 7 Belgium ...
Half-year statement of the liquidity contract of Euronext NV Half-year statement of the liquidity contract of Euronext NV Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 January 2026 – Euronext announced today that the transactions carried out under the liquidity contract entered between Euronext NV and Rothschild Martin Maurel for the period ending 31 December 2025 resulted in the following assets appearing in the liquidity account: • 0 Euronext NV shares • 20,033,888 euros • Number of Buy transaction over the period: 6,506 • Number o...
Colruyt: Guidance reiterated despite weaker-than-expected 1H25/26. Dutch Pension Buyouts: Regulator DNB's view, c.€7bn so far, insurers at 15% market share now. OCI: Dutch investor association VEB and other shareholders take legal action to block Orascom merger. Proximus: CFO Mark Reid to leave Proximus by end of January 2026. Staffing Sector: US temp volume YoY declined vs October; NFP jobs beat expectations. Var Energy: Boosting production bodes well for years to come. Events Calendar
We have reviewed our model on ABN Amro, incorporating the NIBC acquisition, the ambitious growth targets in Wealth Management and the aggressive cost savings targets, mainly driven by FTE reductions. By FY28 we see our income estimates increase by 4.3% and cost estimates decrease by 3.1%. Our new SoTP valuation points to a target price of €29 (vs €25.5), reiterating our Hold recommendation given limited upside.
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
Belgian Telecoms: DIGI Belgium CEO Interview: ‘We are running a marathon, not a sprint' IBA: IBA to install a Rhodotron in East China. Ontex: Another quarter, another profit warning. Theon International: Backlog visibility indeed. Xior: 2026 outlook positive but with no major surprise. Events Calendar
ABN AMRO announces significant risk transfer transaction with Blackstone ABN AMRO announces significant risk transfer transaction with Blackstone 11 December 2025 Today, ABN AMRO announces a significant risk transfer (SRT) transaction with funds manged by Blackstone. This transaction provides first loss protection on a EUR 2 billion portfolio of large corporate loans. The transaction underscores our commitment to creating more room for further profitable growth by actively managing portfolios. We expect the transaction will reduce the bank's risk-weighted assets by EUR 1.6 billion, while...
ABN AMRO kondigt significante risico-overdrachtstransactie aan met Blackstone ABN AMRO kondigt significante risico-overdrachtstransactie aan met Blackstone 11 december 2025 Vandaag kondigt ABN AMRO een significante risico-overdrachtstransactie (SRT) aan met fondsen beheerd door Blackstone. Deze transactie biedt bescherming tegen eerste verliezen op een portefeuille van EUR 2 miljard aan leningen aan grote bedrijven. De transactie onderstreept onze toewijding om actief onze portefeuilles te beheren en meer ruimte te creëren voor verdere winstgevende groei. We verwachten dat de transactie ...
Euronext announces December 2025 quarterly review results of the PSI® Lisbon – 10 December 2025 Euronext today announced the results of the annual review for the PSI®, which will be implemented after markets close on Friday 19 December 2025 and will be effective from Monday 22 December 2025. Results of the December 2025 quarterly review PSI® No changes in the composition of the index The Independent Supervisor retains the right to change the published selection, for instance in the case of a removal due to a takeover, until the publication of the final data after close of Wednesday 17 ...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.